… Study Rationale: Dystonia and Parkinson's disease (PD) are closely related … Some experts estimate that 40 percent of people with PD experience dystonia as an early symptom or complication of treatment. Deep brain stimulation (DBS) is a …

… disease. Developing a new therapeutic can cost up to 2.6 billion dollars and takes many years of screening, … a promising approach to review drugs already developed and with well-known safety profiles in other conditions for … nationwide Norwegian prescription database, which includes comprehensive information about 600 million prescriptions …

… Objective/Rationale:   Clinical trials with a number of agents suggest that the ability of compounds to move through the interstitial spaces of the brain is a …

… upon the research from a prior grant: First-in-human Trial to Assess the Safety and Tolerability of PD01, the First … demonstrated multiple (n=4) subcutaneous vaccinations with two different doses of PD01A (15 and 75 µg) to be safe … clinical development of PD01A. Trial phase:  IB Final Outcome AFFITOPE® PD01A was safe and well tolerated, achieving …

… (PD) and other synucleinopathies are diagnosed based on symptoms and clinical testing. However, these tests can be … and postmortem analysis reveals that 20 to 30% of people with PD are misdiagnosed. Blood tests for detecting … most of the alpha-synuclein found in the blood does not come from the brain. We propose to overcome this problem by …

… “The goal of the Fox Foundation is to close — I really look forward to that day when I get to … and other Parkinson’s disease (PD) experts — people living with the disease and scientists from around the world — … population of the people involved in research. Genetics becomes a starting point for this research and can expand to …